Bayer heads to trial in US antitrust lawsuit over flea, tick medication
By Mike Scarcella
July 22 (Reuters) -A former unit of German life-sciences giant Bayer BAYGn.DE is squaring off in California federal court this week with a petcare startup that claims the company tried to block competition for animal tick and flea treatments.
Jurors in San Jose federal court heard opening statements on Monday in the antitrust case, which was brought by Tevra Brands in 2019 against Bayer Healthcare.
Tevra's lawsuit challenged a discount Bayer provided to some pet specialty retailers and distributors to exclusively carry its products and not to do business with rivals.
“Bayer made it harder and harder for retailers to carry generics," Daniel Owen, a lawyer for Tevra, told the jury on Monday.
Bayer's lawyer Daniel Asimow countered that Tevra failed because it was slow to get to market and had poor relationships with retailers. He told jurors that Bayer competed fairly in a market "crowded" with rivals.
"Generic companies have flourished — just not Tevra," Asimow said.
The trial is expected to last two weeks. Bayer has denied wrongdoing.
Bayer sold Bayer Animal Health, a Bayer Healthcare unit, five years ago to Elanco Animal Health ELAN.N in a $7.6 billion deal. Elanco is not a defendant. Bayer referred a request for comment to Elanco, which did not immediately respond to an inquiry.
Tevra’s attorneys declined to comment.
Americans spend billions of dollars a year on tick and flea treatment for pets, according to an expert for the plaintiffs.
Tevra said it was competing with Bayer’s Advantage and Advantix topical flea and tick treatments, and lost millions of dollars in revenue from its inability to more widely distribute its generic topical imidacloprid, the active ingredient in tick and flea treatment for cats and dogs.
The lawsuit said Bayer’s alleged scheme “ensured that both retailers and consumers pay supra-competitive prices.”
Tevra told the court last week that its co-founder and chairman of the board, Robert Scharf, was expected to testify “about the lucrative opportunity for a generic imidacloprid topical.”
Bayer has argued that its discount program was voluntary.
“The record evidence makes clear that retailers were free to purchase from other suppliers,” Bayer said in a court filing last week.
The case is Tevra Brands LLC v. Bayer Healthcare LLC, U.S. District Court for the Northern District of California, No. 5:19-cv-04312.
For Tevra: Daniel Owen of Polsinelli
For Bayer: Daniel Asimow and Sonia Pfaffenroth of Arnold & Porter Kaye Scholer
Read more:
Bayer must face US company's flea and tick drug antitrust lawsuit
Reporting by Mike Scarcella
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
